Lupus nephritis: Treatment of resistant disease

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 1, 2013, Pages 154-161

  Kalloo, Sean ^a   Aggarwal, Nidhi ^a   Mohan, Prince ^a   Radhakrishnan, Jai ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; STEROID; T LYMPHOCYTE RECEPTOR; TACROLIMUS;

ALOPECIA; ARTICLE; CELL THERAPY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG MEGADOSE; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERTRICHOSIS; IMMUNE RESPONSE; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; META ANALYSIS (TOPIC); NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PLASMAPHERESIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEM CELL TRANSPLANTATION;

DRUG RESISTANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MORBIDITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84872174005     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05870612     Document Type: Article

References (73)

1. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353: 2219-2228, 2005
2. Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Pando J, Steinberg AD, Gourley MF, Klippel JH, Balow JE, Boumpas DT: Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long-term fol- lowup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 46: 995-1002, 2002
3. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed ER, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46: 2121-2131, 2002
4. Hahn BHMM, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, Ramsey-Goldman R, Singh K, Khalighi M, Choi SI, Gogia M, Kafaja S, Kamgar M, Lau C, Martin WJ, Parikh S, Peng J, Rastogi A, Chen W, Grossman JM; American College of Rheumatology: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64: 797-808, 2012
5. Gordon C, Jayne D, Pusey C, Adu D, Amoura Z, Aringer M, Ballerin J, Cervera R, Calvo-Alén J, Chizzolini C, Dayer J, Doria A, Ferrario F, Floege J, Guillevin L, Haubitz M, Hiepe F, Houssiau F, Lesavre P, Lightstone L, Meroni P, Meyer O, Moulin B, O'Reilly K, Praga M, Schulze-Koops H, Sinico R, Smith K, Tincani A, Vasconcelos C, Hughes G: European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 18: 257-263, 2009
6. Kidney Disease Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2: 139-274, 2012
7. Sloan RP, Schwartz MM, Korbet SM, Borok RZ; Lupus Nephritis Collaborative Study Group: Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. J Am Soc Nephrol 7: 299-305, 1996
8. Barr RG, Seliger S, Appel GB, Zuniga R, D'Agati V, Salmon J, Radhakrishnan J: Prognosis in proliferative lupus nephritis: The role of socio-economic status and race/ethnicity. Nephrol Dial Transplant 18: 2039-2046, 2003
9. Mohan S, Radhakrishnan J: Geographical variation in the response of lupus nephritis to mycophenolate mofetil induction therapy. Clin Nephrol 75: 233-241, 2011
10. Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ; Collaborative Study Group: Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 3: 46-53, 2008
11. Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, Wong RW, Au TC: Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 119: 355, e325-e333, 2006
12. Illei GG, Cervera R, Burt RK, Doria A, Hiepe F, Jayne D, Pavletic S, Martin T, Marmont A, Saccardi R, Voskuyl AE, Farge D: Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis 70: 2071-2074, 2011
13. Petri M, Jones RJ, Brodsky RA: High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 48: 166-173, 2003
14. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N; ALMS Group: Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365: 1886-1895, 2011
15. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20: 1103-1112, 2009
16. Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, Fiehn C, de Ramon Garrido E, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R; MAINTAIN Nephritis Trial Group: Azathioprine versus mycophenolate mofetil for long-term immuno- suppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 69: 2083-2089, 2010
17. Dooley MA, Cosio FG, Nachman PH, Falkenhain ME, Hogan SL, Falk RJ, Hebert LA: Mycophenolate mofetil therapy in lupus nephritis: Clinical observations. J Am Soc Nephrol 10: 833-839, 1999
18. Kingdon EJ, McLean AG, Psimenou E, Davenport A, Powis SH, Sweny P, Burns A: The safety and efficacy of MMF in lupus nephritis: A pilot study. Lupus 10: 606-611, 2001
19. Kapitsinou PP, Boletis JN, Skopouli FN, Boki KA, Moutsopoulos HM: Lupus nephritis: Treatment with mycophenolate mofetil. Rheumatology (Oxford) 43: 377-380, 2004
20. Ding L, Zhao M, Zou W, Liu Y, Wang H: Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: A histopathological study. Lupus 13: 113-118, 2004
21. Li L, Wang H, Lin S, et al: Mycophenolate mofetil treatment for diffuse proliferative lupus nephritis: A multicenter clinical trial in China. Zhonghua Nei Ke Za Zhi 41: 476-479, 2002
22. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P: The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14: 931-938, 2008
23. Favre H, Miescher PA, Huang YP, Chatelanat F, Mihatsch MJ: Ciclosporin in the treatment of lupus nephritis. Am J Nephrol 9 [Suppl 1]: 57-60, 1989
24. Manger K, Kalden JR, Manger B: Cyclosporin A in the treatment of systemic lupus erythematosus: Results of an open clinical study. Br J Rheumatol 35: 669-675, 1996
25. Tam LS, Li EK, Leung CB, Wong KC, Lai FM, Wang A, Szeto CC, Lui SF: Long-term treatment of lupus nephritis with cyclosporine A. QJM 91: 573-580, 1998
26. Fu LW, Yang LY, Chen WP, Lin CY: Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Br J Rheumatol 37: 217-221, 1998
27. Dostál C, Tesar V, Rychlík I, Zabka J, Vencovský J, Bartûnková J, Stejskalová A, Tegzova D: Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: A pilot study. Lupus 7: 29-36, 1998
28. Ogawa H, Kameda H, Nagasawa H, Sekiguchi N, Takei H, Tsuzaka K, Amano K, Takeuchi T: Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. Mod Rheumatol 17: 92-97, 2007
29. Ferrario L, Bellone M, Bozzolo E, Baldissera E, Sabbadini MG: Remission from lupus nephritis resistant to cyclophosphamide after additional treatment with cyclosporin A. Rheumatology (Oxford) 39: 218-220, 2000
30. Rihova Z, Vankova Z, Maixnerova D, Dostal C, Jancova E, Honsova E, Merta M, Rysava R, Tesar V: Treatment of lupus nephritis with cyclosporine - an outcome analysis. Kidney Blood Press Res 30: 124-128, 2007
31. Moroni G, Doria A, Mosca M, Alberighi OD, Ferraccioli G, Todesco S, Manno C, Altieri P, Ferrara R, Greco S, Ponticelli C: A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 1: 925-932, 2006
32. Duddridge M, Powell RJ: Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 56: 690-692, 1997
33. Politt D, Heintz B, Floege J, Mertens PR: Tacrolimus- (FK 506) based immunosuppression in severe systemic lupus erythematosus. Clin Nephrol 62: 49-53, 2004
34. Sahin GM, Sahin S, Kantarci G, Ergin H: Mycophenolate mofetil treatment for therapy-resistant glomerulopathies. Nephrology (Carlton) 12: 285-288, 2007
35. Yoshida S, Kotani T, Takeuchi T, Isoda K, Hata K, Watanabe K, Shoda T, Inoue T, Makino S, Hanafusa T: Successful treatment of early intervention with tacrolimus for a patient with lupus nephritis III1V [article in Japanese]. Nihon Rinsho Meneki Gakkai Kaishi 31: 460-464, 2008
36. Cortés-Hernández J, Torres-Salido MT, Medrano AS, Tarrés MV, Ordi-Ros J: Long-term outcomes-mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant 25: 3939-3948, 2010
37. Mok CC, Tong KH, To CH, Siu YP, Au TC: Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An openlabeled pilot study. Kidney Int 68: 813-817, 2005
38. Tse KC, Lam MF, Tang SC, Tang CS, Chan TM: A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus 16: 46-51, 2007
39. Lee T, Oh KH, Joo KW, Kim YS, Ahn C, Han JS, Kim S, Chin HJ: Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis. Lupus 19: 974-980, 2010
40. Miyasaka N, Kawai S, Hashimoto H: Efficacy and safety of tacrolimus for lupus nephritis: A placebo-controlled double-blind multicenter study. Mod Rheumatol 19: 606-615, 2009
41. Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS: Successful treatment of class V1IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 19: 2001-2010, 2008
42. Moroni G, Doria A, Ponticelli C: Cyclosporine (CsA) in lupus nephritis: Assessing the evidence. Nephrol Dial Transplant 24: 15-20, 2009
43. Bartlett RR, Popovic S, Raiss RX: Development of autoimmunity in MRL/lpr mice and the effects of drugs on this murine disease. Scand J Rheumatol Suppl 75: 290-299, 1988
44. Remer CF, Weisman MH, Wallace DJ: Benefits of leflunomide in systemic lupus erythematosus: A pilot observational study. Lupus 10: 480-483, 2001
45. Tam LS, Li EK, Wong CK, Lam CW, Szeto CC: Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 13: 601-604, 2004
46. Wang HY, Cui TG, Hou FF, Ni ZH, Chen XM, Lu FM, Xu FF, Yu XQ, Zhang FS, Zhao XZ, Zhao MH, Wang GB, Qian JQ, Cai GY, Zhu TY, Wang YH, Jiang ZP, Li YN, Mei CL, Zou WZ; China Leflunomide Lupus Nephritis Study Group: Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: A prospective multi-centre observational study. Lupus 17: 638-644, 2008
47. Tam LS, Li EK, Wong CK, Lam CW, Li WC, Szeto CC: Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: An open label trial. Ann Rheum Dis 65: 417-418, 2006
48. Gensburger D, Kawashima M, Marotte H, Kanitakis J, Miossec P: Lupus erythematosus with leflunomide: Induction or reactivation? Ann Rheum Dis 64: 153-155, 2005
49. Goeb V, Berthelot JM, Joly P, Mejjad O, de Quatrebarbes J, Reynaud-Hautin C, Vittecoq O, Le Loet X: Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 44: 823-824, 2005
50. Chan SK, Hazleman BL, Burrows NP: Subacute cutaneous lupus erythematosus precipitated by leflunomide. Clin Exp Dermatol 30: 724-725, 2005
51. Lin CY, Hsu HC, Chiang H: Improvement of histological and immunological change in steroid and immunosuppressive drugresistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 53: 303-310, 1989
52. Levy Y, Sherer Y, George J, Rovensky J, Lukac J, Rauova L, Poprac P, Langevitz P, Fabbrizzi F, Shoenfeld Y: Intravenous immuno- globulin treatment of lupus nephritis. Semin Arthritis Rheum 29: 321-327, 2000
53. Winder A, Molad Y, Ostfeld I, Kenet G, Pinkhas J, Sidi Y: Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: Report of 2 cases. J Rheumatol 20: 495-498, 1993
54. Monova D, Belovezhdov N, Altunkova I, Monov S: Intravenous immunoglobulin G in the treatment of patients with chronic glomerulonephritis: Clinical experience lasting 15 years. Nephron 90: 262-266, 2002
55. Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM: Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 354: 569-570, 1999
56. Orbach H, Tishler M, Shoenfeld Y: Intravenous immunoglobulin and the kidney-a two-edged sword. Semin Arthritis Rheum 34: 593-601, 2004
57. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM; The Lupus Nephritis Collaborative Study Group: A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 326: 1373-1379, 1992
58. Braun N, Erley C, Klein R, Kotter I, Saal J, Risler T: Immuno- adsorption onto protein A induces remission in severe systemic lupus erythematosus. Nephrol Dial Transplant 15: 1367-1372, 2000
59. Stummvoll GH, Aringer M, Smolen JS, Schmaldienst S, Jiménez-Boj E, Horl WH, Graninger WB, Derfler K: IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: A long term observational study. Ann Rheum Dis 64: 1015-1021, 2005
60. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG: Efficacy and safety of rituximab in moderately-to- severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62: 222-233
61. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G; LUNAR Investigator Group: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64: 1215-1226, 2012
62. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I: B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose- escalation trial of rituximab. Arthritis Rheum 50: 2580-2589, 2004
63. Smith KG, Jones RB, Burns SM, Jayne DR: Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 54: 2970-2982, 2006
64. Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, Portales-Pérez D, Baranda L, Abud-Mendoza C, González-Amaro R: Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study. Arthritis Res Ther 8: R83, 2006
65. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA: B-cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients. Rheumatology (Oxford) 44: 1542-1545, 2005
66. Díaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martínez-Berriotxoa A, García-Hernández F, Callejas-Rubio JL, Rascón J, D'Cruz D, Jayne D, Ruiz-Irastorza G, Emery P, Isenberg D, Ramos-Casals M, Khamashta MA; UK-BIOGEAS Registry: Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmun Rev 11: 357-364, 2012
67. Molloy ES, Calabrese LH: Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies. Arthritis Rheum 64: 3043-3051, 2012
68. Tse KC, Li FK, Tang S, Tang CS, Lai KN, Chan TM: Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus 14: 947-952, 2005
69. Kanda H, Kubo K, Tateishi S, Sato K, Yonezumi A, Yamamoto K, Mimura T: Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus 14: 288-292, 2005
70. Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR: Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 173: 7641-7646, 2004
71. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA: Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann Rheum Dis 69: 20-28, 2010
72. Moore AD, Petri MA, Manzi S, Isenberg DA, Gordon C, Senécal JL, St Pierre Y, Joseph L, Penrod J, Fortin PR, Sutcliffe N, Goulet JR, Choquette D, Grodzicky T, Esdaile JM, Clarke AE; Trination Study Group: The use of alternative medical therapies in patients with systemic lupus erythematosus. Arthritis Rheum 43: 1410-1418, 2000
73. Chou CT: Alternative therapies: What role do they have in the management of lupus? Lupus 19: 1425-1429, 2010